For decades, the University of Iowa has been home to some of the most significant advancements in our understanding and treatment of cystic fibrosis. A recent $3.63M/five-year grant from the National Institutes of Health to a multidisciplinary team of researchers led by Drs. David Stoltz and Joseph Zabner may lead to the next ground-breaking discovery.
Cystic fibrosis is a life-shortening lung disease, characterized by airway infection and inflammation, beginning during infancy and leading to respiratory failure. Although new therapies have reduced the suffering of people with this disease and extended their lives, preventing or reducing the initial infection could dramatically improve the course CF takes in an individual’s life. Mutations in the gene encoding CFTR, an ion-conducting channel, underlie the disease, and this impairs two critical airway host defense mechanisms: reduced airway surface liquid (ASL) antimicrobial activity and abnormal mucociliary transport (MCT).
Previous research has shown that abnormally acidic ASL…
View original post 160 more words